RE:RE:RE:RE:RE:RE:RE:A new lexicon for specialty pharmasin my opinion, I think select has a point. its I would argue thats its not entirely just about the language existing in a vacuum, but the language as representative of philosophy. Lets not just talk about profit or accretion but lets also marry those terms with debt control and debt reduction.
I certainly think, going forward, investors will still want to hear about eps growth, profit and accretion when it comes to M&A, but they will also be much more attentive to the balance sheet and debt levels.